|
´õÀ⽺ |
¾à»çÀڰݺ¸À¯ÇÑ ÀÓ¿ø±Þ °øÀåÀå(Á¦¾à,°Ç°½ÄÇ°)ä¿ë
ÃæºÏ Á¦Ãµ½Ã | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
14³â¡è |
ä¿ë½Ã |
12.01 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Market Access(¾à°¡´ã´çÀÚ)/±¹³»majorÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
12.03 |
|
|
JYpartners |
[[¾à»ç, ÇѾà»ç Çʼö]] CRA 2³â ÀÌ»ó °æ·ÂÀÚ OK
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
05.06 |
|
|
¹Ý¼®½áÄ¡(ÁÖ) |
¾à»ç ¹× Á¦Á¦¿¬±¸ÆÀÀå ¸ðÁý
Ãæ³² ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
3³â¡è |
»ó½Ãä¿ë |
10.03 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
MSL(CNSÁ¦Ç°)/±¹³»À¯¸íÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
3³â¡è |
ä¿ë½Ã |
12.12 |
|
|
¼¿ï¿Ü´ë½ºÄ«¿ìÆ® |
(¿Ü±¹°ÔÁ¦¾à»ç)PV 0-3°æ·Â
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
03.11 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Medical Team Manager/Èñ±ÍÁúȯFranchise(±¹³» »óÀ§±ÇÀÇ Á¦
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
7³â¡è |
ä¿ë½Ã |
01.13 |
|
|
JYpartners |
[¿Ü±¹°è(µ¶ÀÏ)] Á¦¾àȸ»ç PM¸ðÁý
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
2³â¡è |
ä¿ë½Ã |
03.11 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
Medical Science Liasion
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
˂ȍ |
°æ·Â¹«°ü |
ä¿ë½Ã |
01.02 |
|
|
JYpartners |
PD Product Manager
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
03.11 |
|
|
(ÁÖ)ÇÁ¶óÀ̸Ӹ®¿¡ÀÌÄ¡¾Ë |
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
3³â¡è |
ä¿ë½Ã |
08.26 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Country Medical Director/À¯·´°èÇÕÀÛÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
˂ȍ |
3³â¡è |
ä¿ë½Ã |
04.06 |
|
|
(ÁÖ)¸®¿ÂÆÄÆ®³Ê½º |
Country Head, Manager, Sr./Jr. cra ±Û·Î¹ú Pharm/cro(ÀçÅÃ
¼¿ï °³²±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
12.01 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
¸¶ÀϽºÅæ¼Ä¡ Á¦¾àä¿ë°ø°í ¸ðÀ½
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
1³â¡è |
ä¿ë½Ã |
12.03 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Medical Doctor(ÀÇÇнÇÀå) Á¦¾àÀÇ»ç ºÐÀ» ã½À´Ï´Ù.
¼¿ï °³²±¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
°æ·Â¹«°ü |
ä¿ë½Ã |
10.21 |
|